Drug Trial Radar · NCT00546351
Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy.
Last checked: Nov 20, 2026Latest source record: Sep 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
621
Actual
Start
May 2004
Primary completion
Jan 2011
Study completion Jan 2011
Sponsor
- Lead sponsor
- UCB PharmaUCB
- Sponsor type
- Industry
- First posted
- Oct 18, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
SP746 (NCT00546351) is a multi-center, open-label, follow-on trial. The purpose of this trial is to assess safety and tolerability of long-term exposure of lacosamide (previously referred to as SPM 927) in subjects with painful distal diabetic neuropathy.
Conditions
- Painful Diabetic Neuropathy
Interventions
LacosamideDrug
50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing the Occurrence of at Least One Treatment-emergent Adverse Event (TEAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (Approximately 6.5 Years).Time frame: From entry Visit 1 through end of treatment (approximately 6.5 years)
- Number of Participants Experiencing the Occurrence of at Least One Serious Adverse Event (SAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (Approximately 6.5 Years).Time frame: From entry Visit 1 through end of treatment (approximately 6.5 years)
Locations
101 sites in 15 countries. Site status is shown where the registry gives one.
180
Vienna, Austria
183
Vienna, Austria
003
Antwerp, Belgium
006
Bonheiden, Belgium
002
Genk, Belgium
001
Leuven, Belgium
005
Merksem, Belgium
004
Roeselare, Belgium
011
Pleven, Bulgaria
014
Plovdiv, Bulgaria
017
Plovdiv, Bulgaria
019
Rousse, Bulgaria
012
Sofia, Bulgaria
013
Sofia, Bulgaria
015
Sofia, Bulgaria
016
Sofia, Bulgaria
210
Stara Zagora, Bulgaria
010
Varna, Bulgaria
028
Brno, Czechia
220
Chomutov, Czechia
026
Litoměřice, Czechia
027
Olomouc, Czechia
024
Ostrava-Poruba, Czechia
029
Písek, Czechia
021
Prague, Czechia
022
Prague, Czechia
192
Kuopio, Finland
034
Lisieux, France
031
Nevers, France
040
Bad Saarow, Germany
052
Beckum, Germany
049
Berlin, Germany
051
Berlin, Germany
056
Berlin, Germany
242
Berlin, Germany
249
Berlin, Germany
247
Bochum, Germany
041
Hamburg, Germany
045
Hamburg, Germany
054
Hamburg, Germany
Showing 40 of 101 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.